Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
An update on emerging drugs for Hodgkin lymphoma.
[hodgkin lymphoma, classical]
Most
patients
with
Hodgkin
lymphoma
(
HL
)
are
cured
with
modern
combined
modality
first
-line
treatments
.
Even
~
50
%
of
patients
with
relapsed
/
refractory
HL
can
be
cured
with
high
-dose
chemotherapy
(
HDCT
)
and
autologous
stem
cell
transplantation
.
However
,
chemotherapy
and
radiotherapy
cause
significant
acute
and
long
-term
side
effects
and
patients
relapsing
after
HDCT
have
a
dismal
prognosis
.
New
drugs
are
therefore
needed
to
reduce
the
toxicity
of
first
-line
treatments
and
to
increase
the
efficacy
of
relapse
treatments
.
Moreover
,
new
drugs
are
needed
for
the
treatment
of
older
patients
with
HL
because
results
with
current
treatments
are
disappointing
.
This
article
discusses
promising
new
drugs
for
the
treatment
of
classical
HL
that
have
been
evaluated
in
the
last
years
.
There
is
a
focus
on
the
antibody
drug
conjugate
brentuximab
vedotin
and
its
potential
for
the
future
treatment
of
HL
.
Moreover
,
data
on
the
histone
deacetylase
inhibitors
panobinostat
and
mocetinostat
,
the
mammalian
target
of
rapamycin
inhibitor
everolimus
,
the
Janus
kinase
2
inhibitor
SB
1518
and
the
immunomodulatory
agent
lenalidomide
are
summarized
.
Besides
improving
the
prognosis
of
relapsed
patients
,
new
drugs
should
be
used
to
replace
the
most
toxic
compounds
in
first
-line
therapy
to
reduce
acute
and
long
-term
toxicities
of
the
treatment
.
Diseases
Validation
Diseases presenting
"hodgkin lymphoma"
symptom
esophageal adenocarcinoma
hodgkin lymphoma, classical
monosomy 21
primary effusion lymphoma
severe combined immunodeficiency
systemic capillary leak syndrome
waldenström macroglobulinemia
This symptom has already been validated